ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Renal Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1617185
Renoprotective Effects of GHRH Agonist MR409 Is Associated with Reduced Oxidative Stress and Ferroptosis in Diabetic Mice
Provisionally accepted
- 1Shenyang Medical College, Shenyang, China
- 2Second Affiliated Hospital of Shenyang Medical College, Shenyang, Liaoning Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
MR409, a synthetic growth hormone-releasing hormone (GHRH) analogue, has demonstrated therapeutic potential in enhancing islet cell transplantation efficacy in diabetes mice and exerts beneficial effects on cardiovascular diseases. The present study investigated the renoprotective effects of MR409 on db/db and streptozotocin (STZ)-induced diabetic mice, focusing on its role in modulating oxidative stress and ferroptosis. db/db or STZ mice combined with high fat diet were used to establish the type 2 diabetic models. MR409 (15 μg/mouse/day) was subcutaneously administrated for 8 weeks. Treatment with MR409 significantly improved renal function, reduced the renal injury and fibrosis in both db/db and STZ-induced diabetic mice. MR409 increased the expression of renal GHRH receptor without affecting plasma level of the growth hormone. It attenuated oxidative stress, evidenced by decreased expressions of NADPH oxidase subunits p22phox, gp91phox, reduced dihydroethidium oxidative fluorescence intensity, and lowered renal expression of malondialdehyde and 4hydroxynonenal in db/db mice. Meanwhile, MR409 inhibited ferroptosis, as indicated by upregulating the expressions of glutathione peroxidase 4, nuclear factor erythroid 2-related factor, ferritin heavy chain and downregulating transferrin receptor expression, alongside restoring renal glutathione level in db/db mice. Notably, MR409 activated the peroxisome proliferator-activated receptor and its downstream targeted gene Klotho in diabetic kidney. Collectively, the present study demonstrated that MR409 alleviates diabetic nephropathy, mitigates oxidative stress and ferroptosis, offering a novel therapeutic insight for diabetic nephropathy.
Keywords: Growth hormone-release hormone analogue, diabetic nephropathy, Oxidative Stress, ferroptosis, klotho Diabetic Nephropathy, GHRH analogues
Received: 24 Apr 2025; Accepted: 07 Aug 2025.
Copyright: © 2025 Zhou, Liu, Fu, Tang, Zhang, Cai, Liu, Jia and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ming-Sheng Zhou, Shenyang Medical College, Shenyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.